Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting

Phase 2

Phase 3

ClazakizumabCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Sponsor:

CSL Behring

Code:

NCT05485961

Conditions

Atherosclerotic Cardiovascular Disease

End Stage Kidney Disease

Atherosclerotic Cardiovascular Disease in Patients With ESKD

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CSL300

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by CSL Behring on 2025-05-11.